Celldex Therapeutics
CLDX
95 hedge funds and large institutions have $23.2M invested in Celldex Therapeutics in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 31 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.56% less ownership
Funds ownership: 2.53% → 1.97% (-0.56%)
7% less funds holding
Funds holding: 102 → 95 (-7)
15% less call options, than puts
Call options by funds: $11K | Put options by funds: $13K
15% less capital invested
Capital invested by funds: $27.4M → $23.2M (-$4.23M)
32% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 31
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$524K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$294K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$197K |
| 4 |
Two Sigma Investments
New York
|
+$170K |
| 5 |
Two Sigma Advisers
New York
|
+$159K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$689K |
| 2 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
-$620K |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$405K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$323K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$299K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KF
101
Krilogy Financial
St. Louis,
Missouri
| – | +$280 | +40 | New |
|
102
JP Morgan Chase
New York
| – | +$413 | +59 | +88% |
|
|
RMAM
103
Raab & Moskowitz Asset Management
Chatham,
New Jersey
| – | +$469 | +67 | New |
|
CLDX Hedge Fund Activity: Q3 2018 in Review
95 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2018, worth a combined $23.2M — down 15% from $27.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CLDX and 9 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 21 added.
The largest buyer was Renaissance Technologies, adding an estimated $524K. The largest seller was Goldman Sachs, cutting an estimated $689K.
- 95 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2018, down from 102 in Q2 2018.
- Funds reported $23.2M of Celldex Therapeutics stock for Q3 2018, down 15% quarter-over-quarter.
- 9 funds opened new Celldex Therapeutics positions in Q3 2018 and 16 closed out, a net change of -7 holders.
- The largest Celldex Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $524K added.
- The largest Celldex Therapeutics seller in Q3 2018 was Goldman Sachs, an estimated $689K sold.
Based on aggregated 13F filings for Q3 2018.